A retrospective exploratory analysis of tumor tissue was unable to identify any predictive biomarkers of everolimus efficacy in patient subgroups defined by each of the 4 most frequently altered genes/pathways, when assessed individually (PIK3CA, CCND1, TP53 and FGFR1). Here, PIK3CA is linked to neoplasm.